Ku Ja Hyeon, Shin Jung Ki, Cho Min Chul, Myung Jae Kyung, Moon Kyung Chul, Paick Jae-Seung
Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
Scand J Urol Nephrol. 2009;43(6):445-53. doi: 10.3109/00365590903337896.
To evaluate the effects of dutasteride on the expression of angiogenesis markers in rat and human prostates.
Eight-week-old male Sprague-Dawley rats were divided into three groups of six each according to dutasteride dose, including the control group (regular diet), 2.5 mg group (2.5 mg/kg dutasteride) and 5.0 mg group (5.0 mg/kg dutasteride). A total of 41 patients awaiting transurethral resection of the prostate (TURP) were divided into two groups: 20 patients received no medication and 21 received 0.5 mg dutasteride daily for 2-4 weeks until TURP.
At 2 weeks, dutasteride effected a significant decrease in body weight and prostate weight compared with the control rat group. Analysis by reverse transcription-polymerase chain reaction and Western blot revealed that hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression was lower in the dutasteride-treated groups than in the control group, except for HIF-1alpha protein. HIF-1alpha and VEGF expression was similar in the 2.5 mg and 5.0 mg groups. Human prostate tissues demonstrated homogeneous staining of HIF-1alpha and VEGF with regard to extent, intensity and intracellular location in both groups. There was no significant difference in microvessel density between the two groups.
The expression of HIF-1alpha and VEGF in rat prostates is suppressed by dutasteride. However, less than 4 weeks of dutasteride administration does not suppress the expression of HIF-1alpha, VEGF and microvessel density in human prostate tissue. Further clinical investigation with dutasteride including a larger, placebo-controlled study is warranted to establish the mechanism and duration of dutasteride.
评估度他雄胺对大鼠和人类前列腺中血管生成标志物表达的影响。
将8周龄雄性Sprague-Dawley大鼠根据度他雄胺剂量分为三组,每组6只,包括对照组(常规饮食)、2.5毫克组(2.5毫克/千克度他雄胺)和5.0毫克组(5.0毫克/千克度他雄胺)。共有41例等待经尿道前列腺切除术(TURP)的患者被分为两组:20例患者未接受药物治疗,21例患者每天接受0.5毫克度他雄胺治疗2 - 4周,直至进行TURP。
在2周时,与对照大鼠组相比,度他雄胺使体重和前列腺重量显著降低。通过逆转录 - 聚合酶链反应和蛋白质印迹分析显示,除HIF - 1α蛋白外,度他雄胺治疗组中缺氧诱导因子 - 1α(HIF - 1α)和血管内皮生长因子(VEGF)的表达低于对照组。HIF - 1α和VEGF在2.5毫克组和5.0毫克组中的表达相似。两组人类前列腺组织在HIF - 1α和VEGF的范围、强度和细胞内定位方面显示出均匀染色。两组之间微血管密度无显著差异。
度他雄胺抑制大鼠前列腺中HIF - 1α和VEGF的表达。然而,度他雄胺给药少于4周不会抑制人类前列腺组织中HIF - 1α、VEGF的表达和微血管密度。有必要进行包括更大规模、安慰剂对照研究在内的度他雄胺进一步临床研究,以确定度他雄胺的作用机制和持续时间。